Thymalin regulatory status
Current status of Thymalin in the United States: Unscheduled. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Thymalin?
Regulatory: UnscheduledWADA: WADA status unclearVerified: Verified Sep 22, 2026
- FDA and compounding
- Thymalin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. As an animal tissue extract of undefined composition it is not a candidate for 503A bulk compounding, and it is not eligible for 503B outsourcing. It is registered as a prescription drug in Russia and some neighboring countries. Products sold in the United States under this name are not lawful for human use.
- WADA
- WADA status unclear
- Access path
- Not legally available in the United States: no approved product and no 503A bulks listing.
- Prescription drug in Russia and some neighboring countries.
- Products labeled research use only are not lawful for human use and are not verified for identity or purity.
Full Thymalin page: evidence, dosing in the literature, and sources
How has the status of Thymalin changed over time?
No dated regulatory event has been recorded for Thymalin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Thymalin and the source of each dated event.